SCHEMBL25923642

SCHEMBL25923642

CCC(=O)N1CCC2(CC1)CC(CC(C)C)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.39
ALDH1A1 P00352 3/20 0.38
CYP2D6 P10635 3/20 0.37
EPHX2 P34913 5/20 0.36
EPHX1 P07099 2/20 0.36
OPRM1 P35372 1/20 0.36
CHRNB2 P17787 2/20 0.34
CHRNA3 P32297 2/20 0.34
CHRNA4 P43681 2/20 0.34
CHRNB3 Q05901 1/20 0.34
CHRNA6 Q15825 1/20 0.34
POLB P06746 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
CHRNB4 P30926 1/20 0.33
CHRNA7 P36544 1/20 0.33
BLM P54132 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23842177 0.85 GPR119 (0.37) NAMPTALDH1A1CYP2D6EPHX2EPHX1
SCHEMBL29325176 0.84 PIK3CD (0.43) ALDH1A1CYP2D6EPHX2CYP3A4CYP1A2
SCHEMBL22904926 0.83 CYP2D6 (0.38) NAMPTALDH1A1CYP2D6CHRNB2CHRNA3
SCHEMBL25730183 0.81 OPRM1 (0.41) NAMPTALDH1A1EPHX2EPHX1OPRM1
SCHEMBL24764434 0.81 ALDH1A1 (0.41) NAMPTALDH1A1CYP2D6EPHX2EPHX1
SCHEMBL18913868 0.78 OPRM1 (0.41) NAMPTALDH1A1EPHX2EPHX1OPRM1
SCHEMBL12876362 0.78 EPHX2 (0.46) ALDH1A1EPHX2EPHX1CHRNB2CHRNA3
SCHEMBL29307328 0.77 OPRM1 (0.43) NAMPTALDH1A1EPHX2EPHX1OPRM1
SCHEMBL29325180 0.77 GPR119 (0.51) NAMPTCYP2D6EPHX2GPR119
SCHEMBL23568491 0.76 CYP2D6 (0.32) CYP2D6GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192578-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 NAMPT 1694/4885ALDH1A1 2776/4885CYP2D6 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.